Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1959 1
1961 1
1963 1
1964 1
1965 1
1966 1
1969 1
1970 3
1971 8
1972 2
1973 2
1974 1
1975 30
1976 37
1977 31
1978 32
1979 32
1980 32
1981 45
1982 48
1983 62
1984 72
1985 85
1986 85
1987 82
1988 101
1989 143
1990 181
1991 174
1992 156
1993 194
1994 223
1995 229
1996 259
1997 276
1998 284
1999 291
2000 399
2001 410
2002 419
2003 491
2004 529
2005 627
2006 605
2007 690
2008 749
2009 831
2010 955
2011 1003
2012 1147
2013 1222
2014 1379
2015 1523
2016 1676
2017 1730
2018 1833
2019 2113
2020 2680
2021 3157
2022 3236
2023 3215
2024 1525

Text availability

Article attribute

Article type

Publication date

Search Results

33,648 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Advanced Prostate Cancer.
Teo MY, Rathkopf DE, Kantoff P. Teo MY, et al. Annu Rev Med. 2019 Jan 27;70:479-499. doi: 10.1146/annurev-med-051517-011947. Annu Rev Med. 2019. PMID: 30691365 Free PMC article. Review.
The therapeutic landscape of prostate cancer has been transformed over the last decade by new therapeutics, advanced functional imaging, next-generation sequencing, and better use of existing therapies in early-stage disease. ...We also discuss advances …
The therapeutic landscape of prostate cancer has been transformed over the last decade by new therapeutics, advanced functiona …
Pancreatic cancer.
Mizrahi JD, Surana R, Valle JW, Shroff RT. Mizrahi JD, et al. Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0. Lancet. 2020. PMID: 32593337 Review.
Systemic chemotherapy combinations including FOLFIRINOX (5-fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel remain the mainstay of treatment for patients with advanced disease. Data on the benefit of PARP inhi …
Systemic chemotherapy combinations including FOLFIRINOX (5-fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and …
Evolving therapeutic landscape of advanced hepatocellular carcinoma.
Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Yang C, et al. Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):203-222. doi: 10.1038/s41575-022-00704-9. Epub 2022 Nov 11. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36369487 Review.
Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide. A large proportion of patients with HCC are diagnosed at advanced stages and are only amenable to systemic therapies. We have witnessed the evolution of systemic …
Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide. A large proportion of patients with HCC are diagnosed …
Advances in systemic therapies for triple negative breast cancer.
Leon-Ferre RA, Goetz MP. Leon-Ferre RA, et al. BMJ. 2023 May 30;381:e071674. doi: 10.1136/bmj-2022-071674. BMJ. 2023. PMID: 37253507 Review.
In the operable setting, efforts to improve outcomes have focused on escalation of systemic therapy and a shift toward preoperative delivery followed by a response adapted approach to postoperative systemic therapy. An improved understanding of tumor b …
In the operable setting, efforts to improve outcomes have focused on escalation of systemic therapy and a shift toward preoper …
Advances in systemic therapy for non-small cell lung cancer.
Miller M, Hanna N. Miller M, et al. BMJ. 2021 Nov 9;375:n2363. doi: 10.1136/bmj.n2363. BMJ. 2021. PMID: 34753715 Review.
The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. ...For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduct …
The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. ...F …
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.
Wang Y, Deng B. Wang Y, et al. Cancer Metastasis Rev. 2023 Sep;42(3):629-652. doi: 10.1007/s10555-023-10084-4. Epub 2023 Feb 2. Cancer Metastasis Rev. 2023. PMID: 36729264 Review.
Despite the emergence of new systemic therapies, survival rates for advanced HCC patients remain low. ...Research on biomarkers for HCC treatment is also advancing. Here, we explore the molecular mechanism that are associated with HCC development, summ …
Despite the emergence of new systemic therapies, survival rates for advanced HCC patients remain low. ...Research on bi …
Brain metastases.
Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS, Chang SD. Achrol AS, et al. Nat Rev Dis Primers. 2019 Jan 17;5(1):5. doi: 10.1038/s41572-018-0055-y. Nat Rev Dis Primers. 2019. PMID: 30655533 Review.
Brain metastases are thought to occur via seeding of circulating tumour cells into the brain microvasculature; within this unique microenvironment, tumour growth is promoted and the penetration of systemic medical therapies is limited. Development of brain metastase …
Brain metastases are thought to occur via seeding of circulating tumour cells into the brain microvasculature; within this unique microenvir …
Nanocarrier-based drug combination therapy for glioblastoma.
Zhao M, van Straten D, Broekman MLD, Préat V, Schiffelers RM. Zhao M, et al. Theranostics. 2020 Jan 1;10(3):1355-1372. doi: 10.7150/thno.38147. eCollection 2020. Theranostics. 2020. PMID: 31938069 Free PMC article. Review.
The current achievements in treating glioblastoma (GBM) patients are not sufficient because many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem cells, drug efflux pumps and DNA damage repair mechanisms. Drug combination therapies have s …
The current achievements in treating glioblastoma (GBM) patients are not sufficient because many challenges exist, such as tumor heterogenei …
Pancreatic cancer treatment: better, but a long way to go.
Torphy RJ, Fujiwara Y, Schulick RD. Torphy RJ, et al. Surg Today. 2020 Oct;50(10):1117-1125. doi: 10.1007/s00595-020-02028-0. Epub 2020 May 30. Surg Today. 2020. PMID: 32474642 Free PMC article. Review.
Remarkable progress has been made in treating pancreatic cancer over the past century, including refinement of our surgical techniques and improvements in adjuvant and neoadjuvant therapies. Despite these advances, the incidence of pancreatic cancer is rising global …
Remarkable progress has been made in treating pancreatic cancer over the past century, including refinement of our surgical techniques and i …
Molecular therapies and precision medicine for hepatocellular carcinoma.
Llovet JM, Montal R, Sia D, Finn RS. Llovet JM, et al. Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. doi: 10.1038/s41571-018-0073-4. Nat Rev Clin Oncol. 2018. PMID: 30061739 Review.
Despite the fact that surveillance programmes lead to early diagnosis in 40-50% of patients, at a point when potentially curative treatments are applicable, almost half of all patients with HCC ultimately receive systemic therapies. Sorafenib was the first system …
Despite the fact that surveillance programmes lead to early diagnosis in 40-50% of patients, at a point when potentially curative treatments …
33,648 results
You have reached the last available page of results. Please see the User Guide for more information.